Novel founder variant in the S-antigen visual arrestin gene <i>SAG</i> is the most prevalent cause of autosomal dominant retinitis pigmentosa in Singaporean Chinese.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 40461169.
- Also identified by DOI 10.1136/jmg-2025-110775.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To characterise a novel founder variant in the <i>SAG</i> gene causing autosomal dominant retinitis pigmentosa (AD-RP) in Singaporean Chinese individuals. Single-centre prospective observational cohort study. Unrelated probands with AD-RP and their affected relatives were recruited from a tertiary eye hospital in Singapore. Genetic analysis was performed using whole exome sequencing and targeted gene panel testing. Clinical phenotyping included best-corrected visual acuity (BCVA), multimodal imaging and visual field assessments. In silico analyses were conducted to assess variant pathogenicity and conservation. We identified a novel heterozygous <i>SAG</i> variant, NM_000541.5:c.442G>A (p.Gly148Arg), in five unrelated families of Southern Chinese descent. A shared haplotype of 3.2 Mb among four families suggested a founder effect. Affected individuals presented with mid-life onset nyctalopia (median age 44 years), progressive BCVA loss after age 40 and severe visual field constriction by the fifth decade. Fundus imaging revealed diffuse retinal pigment epithelium atrophy and perivascular pigmentation. In silico predictions suggest that p.Gly148Arg disrupts conformational changes that are required for rhodopsin modulation. The <i>SAG</i> c.442G>A (p.Gly148Arg) variant represents the first reported <i>SAG</i>-related AD-RP founder variant in ethnic Chinese individuals. Its phenotypic resemblance to the previously described <i>SAG</i> c.440G>T (p.Cys147Phe) variant underscores a common disease mechanism. These findings expand the genetic landscape of AD-RP and highlight <i>SAG</i> as a potential therapeutic target.
Medical subject headings
- Arrestin
- Founder Effect
- Retinitis Pigmentosa